Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2004 / Cilt: 9 - Sayı: 3

Combined use of vancomycin and meropenem in patient with acute intermittent porphyria: A case report

Akut intermittant porfirili bir vakada Vankomisin ve meropenemin birlikte kullanımı

Pages
225–227
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper we reported a patient with AIP treated with combined vancomycin plus meropenem therapy because of lifethreatening nosocomial sepsis and had not any side effect.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acute intermittent porphyria (AIP) is an autosomal dominant disorder that leads to abdominal pain with unknown etiology, nausea, acute peripheric and/or central nervous system disfunctions, hyponatremia and with existence of phorphobilinogen in urine during acute attacks.
📊
Key Findings & Data:Porphyria attacks arise from outer induction of heme synthesis in liver such as drugs that induces mithocondrial cytochrom P-450.
💡
Conclusion & Impact:In this paper we reported a patient with AIP treated with combined vancomycin plus meropenem therapy because of lifethreatening nosocomial sepsis and had not any side effect.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tienamisinler · Vankomisin · Porfiri

Abstract

Acute intermittent porphyria (AIP) is an autosomal dominant disorder that leads to abdominal pain with unknown etiology, nausea, acute peripheric and/or central nervous system disfunctions, hyponatremia and with existence of phorphobilinogen in urine during acute attacks. Young females are more often symptomatic than males. Porphyria attacks arise from outer induction of heme synthesis in liver such as drugs that induces mithocondrial cytochrom P-450. A few antibiotics are considered as safe in patients with porphyria. A quite less previous case were reported in literature about uses of vancomycin and meropenem seperately. However vancomycin plus meropenem combination therapy was not reported in any case with porphyria. In this paper we reported a patient with AIP treated with combined vancomycin plus meropenem therapy because of lifethreatening nosocomial sepsis and had not any side effect.

Özet

Akut intermittant porfiri (AİP), nedeni açıklanamayan karın ağrısı, akut periferik ya da santral sinir sistemi disfonksiyonu, hiponatremi ve ataklar sırasında idrarda porfobilinojen olması ile ortaya çıkan otozomal dominant bir hastalıktır. Genç kadınlar daha çok semptomatik olurlar. Porfiri atakları, özellikle mitokondriyal sitokrom P-450'yi indükleyen ilaçlarla olduğu gibi karaciğerde hem sentezinin dışarıdan uyarılması ile ortaya çıkar. Porfirili hastalarda oldukça az sayıda antibiyotiğin kullanımı güvenli kabul edilmektedir. Literatürde vankomisin veya meropenem kullanımı ile ilgili sınırlı sayıda vaka bildirilmiştir. Ancak vankomisin ve meropenemin birlikte kullanılmış olduğu duruma rastlayamadık. Bu yazıda AİP atağı sırasında, hayatı tehdit eden nozokomiyal sepsis nedeniyle vankomisin ve meropenemin birlikte kullanıldığı ve herhangi bir istenmeyen etkinin ortaya çıkmadığı bir vaka bildirilmiştir.

🔖

Cite This Article

ŞENCAN, İ., YILMAZ, Z., ÖZDEMİR, D. (2004). Combined use of vancomycin and meropenem in patient with acute intermittent porphyria: A case report. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 9 - Sayı: 3, 225–227. https://ajindex.com/articles/210306

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Andersen EK. The porphyrias. In: Goldman L, Bennett JC (eds). Cecil Textbook of Medicine. Philadelphia: WB Saunders Company, 2000:1123-30. 2.Minder EI. The porphyrias. In: Rakel ER, Bope TE (eds). 2002 Conn's Current Theraphy. Philadelphia: WB Saunders Company, 2002:446-50. 3.Parish LC. Newer concepts in - antimicrobial therapy. Adv Exp Med Biol 1999
  2. Jarry C, Bensouda L, Jonville-Bera AP, Autret-Leca E. Porphyria and drugs (abst). Arch Pediatr 2002
  3. Kliasova GA, Savchenko VG, Parovichnikova EN, Tol-kacheva TV, Shulutko EM, Khoroshko ND. Use of me-ropenem in patients with neutropenia (abst). Antibiot Khimioter 1998
  4. Hift R, Sohnius U, Meissner PN. Safety of vancomycin in acute porphyria. Br J Clin Pharmacol.l990
  5. Livermore DM. Bacterial resistance: Origin, epidemiology, and impact. Clin Infect Dis 2003
  6. 36(Suppl 1): 11-23. 8.Fekelty R. Vancomycin, teicoplanin and the streptogra-mins
  7. quinopristin and dalfopristin. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 5^ ed. Pennsylvania: Churchill Livingstone,. 2000:382-92. 9.Chamber FH. Other beta-lactam antibiotics. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 5^ ed. Pennsylvania: Churchill Livingstone, 2000:291-9.